Table 1.
ATR alterations in nasal natural killer (NK)/T‐cell lymphoma (NKTCL) and chronic active Epstein–Barr virus infection (CAEBV) cell lines
| Cell line | Patient/ sample | Original disease | EBV | Nucleotide change | Predicted effect | Mutation‐positive clones (%) | Reference no. |
|---|---|---|---|---|---|---|---|
| NKTCL | |||||||
| HANK‐1 | 46F LN | Nasal‐type (at diagnosis) | + | WT | 15 | ||
| NK‐92 | 50 M PB | NHL with LGL cells (at diagnosis) | + | del exon 29–34 (867 bp) | In‐frame | 50 | 16 |
| SNK‐6 | 62 M TU | Nasal‐type | + | del exon 29–34 (867 bp) del 65 bp (in exon 41) | In‐frame Frameshift | 50 30 | 17 |
| SNT‐8 | 48F TU | Nasal‐type | + | WT | 17 | ||
| YT | 15 M PF | ALL + thymoma (at relapse) | + | WT | 18 | ||
| KHYG‐1 | 45F PB | Aggressive NK‐cell leukemia (at diagnosis) | – | WT | 19 | ||
| MOTN‐1 | 63F PB | (T‐LGL/T‐CLL) in chronic phase | – | WT | 20 | ||
| MTA | 58F PB | Aggressive NK‐like T‐cell leukemia/ lymphoma | – | WT | 21 | ||
| CAEBV | |||||||
| AIK‐T4 | 9F PB | Severe chronic active EBV infection | + | del exon 18 (131 bp) | Frameshift | 50% | 22 |
| SIS | 1 M PB | Severe chronic active EBV infection | + | WT | 22 | ||
| SKN | 6 M PB | Severe chronic active EBV infection | + | WT | 22 | ||
ALL, acute lymphoblastic leukemia; F, female; LN, lymph node; M, Male; NHL, non‐Hodgkin lymphoma; PB, peripheral blood; PF, pericardial fluid; T‐CLL, T‐cell chronic lymphocytic leukemia; T‐LGL, T‐cell large granular lymphocyte leukemia; TU, tumor tissue; WT, wild type.